drugset / Trial / NCT00829998

Zaleplon 10mg Capsules Under Fasting Conditions

NCT00829998

Phase 1 Completed 40 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to compare the relative bioavailability of Zaleplon 10 mg Capsules manufactured by TEVA Pharmaceuticals USA and Sonata® 10 mg Capsules manufactured by Wyeth Laboratories in healthy, non-smoking adults under fasting conditions.

Timeline

Start
2004-02
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Zaleplon Small molecule 10 mg

Indications

No indication recorded.